News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- PRReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of DirectorsBringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A Expertise ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: "Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital,
- FDAFDA Approval for FINTEPLA issued to ZOGENIX INCSubmission status for ZOGENIX INC's drug FINTEPLA (SUPPL-9) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 05/30/2023. Application Category: NDA, Application Number: 212102, Application Classification: REMS
- FDAFDA Approval for FINTEPLA issued to ZOGENIX INCSubmission status for ZOGENIX INC's drug FINTEPLA (SUPPL-6) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 01/03/2023. Application Category: NDA, Application Number: 212102, Application Classification: Labeling
- FDAFDA Approval for FINTEPLA issued to ZOGENIX INCSubmission status for ZOGENIX INC's drug FINTEPLA (SUPPL-5) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 06/15/2022. Application Category: NDA, Application Number: 212102, Application Classification: Labeling
- FDAFDA Approval for FINTEPLA issued to ZOGENIX INCSubmission status for ZOGENIX INC's drug FINTEPLA (SUPPL-3) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 03/25/2022. Application Category: NDA, Application Number: 212102, Application Classification: Efficacy
- FDAFDA Approval for FINTEPLA issued to ZOGENIX INCSubmission status for ZOGENIX INC's drug FINTEPLA (SUPPL-3) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 212102, Application Classification: Efficacy
- FDAFDA Approval for FINTEPLA issued to ZOGENIX INCSubmission status for ZOGENIX INC's drug FINTEPLA (SUPPL-1) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 212102, Application Classification: Labeling
- NEWSThe Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPOHere's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MEI Pharma Says FDA Recommends Additional Phase 3 Study For Facilitating Regulatory Filing For Zandelisib As Blood Cancer Treatment Option MEI Pharma, Inc. (NASDAQ:MEIP) and Japanese pharma company Kyowa Kirin said the FDA had r required a randomized trial to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates, including zandelisib. The companies were hoping to get marketing authorization for zandelisib via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study. Zandelisib is being develope
- NEWSBenzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 21, 2022: BA, COIN, NILE, ZGNX, MULNToday's 5 Stock Ideas: Boeing (BA) - Shares were down 6% Monday morning following the crash of a China Eastern Airlines (CEA) Boeing 737 aircraft in China. Shares of China Eastern Air were also lower, down about 12%. Coinbase (COIN) - A new short by notable short seller and manager of hedge fund Kynikos, Jim Chanos. BitNile (NILE) - A penny stock play on a bitcoin mining company. Shares were up about 80% on Monday; the stock flirted with the $1 level. The Benzinga newsdesk did not see news to justify the move higher. While the company did announce its TurnOnGreen subsidiary would be acquired, the stock was moving prior to the M&A news. Zogenix (ZGNX) - An FDA pla
- NEWSThe Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & EarningsBiotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week. Synthetic Biologics, Inc. (NYSE:SYN) was among the biggest advancers, as the stock reacted to its quarterly results. On the other hand, Nektar Therapeutics (NASDAQ:NKTR) came under pressure following negative results from a late-study of its investigational cancer drug in combination of Bristol-Myers Squibb Company's (NYSE:BMY) Opdivo. Bristol-Myers Squib, meanwhile, received the Food and Drug Administration's approval for its Lag-3 antibody relatilimab, in combination with
- SECSEC Form 15-12B filed by Zogenix Inc.15-12B - ZOGENIX, INC. (0001375151) (Filer)
- INSIDERSEC Form 4: Smith Michael P closing all direct ownership in the company (withholding obligation)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Breitmeyer James B closing all direct ownership in the company (for tax liability)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4 filed by Stutts Mary E. to satisfy withholding obligation4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Wiggins Mark C closing all direct ownership in the company (tax withholding)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4 filed by Bock Louis C (tax withholding)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Tannenbaum Renee P closing all direct ownership in the company to satisfy withholding tax4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Farfel Gail M closing all direct ownership in the company (for tax liability)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Mast Erle T closing all direct ownership in the company (for tax liability)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Galer Bradley S. closing all direct ownership in the company (tax withholding)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4 filed by Loewy Caroline M (withholding tax)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4 filed by Garner Cam L (for withholding tax)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Mitchell Shawnte closing all direct ownership in the company (tax withholding)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Farr Stephen J closing all direct ownership in the company (tax withholding)4 - ZOGENIX, INC. (0001375151) (Issuer)
- INSIDERSEC Form 4: Waynick Denelle J closing all direct ownership in the company (tax liability)4 - ZOGENIX, INC. (0001375151) (Issuer)
ZGNX FAQ
7 questionsWhat does Zogenix Inc. do?
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy...Where does ZGNX stock trade?
Zogenix Inc. (ZGNX) is listed on NASDAQ.What sector and industry is ZGNX in?
Zogenix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zogenix Inc. go public?
Zogenix Inc. (ZGNX) completed its IPO in 2010.What are analysts saying about ZGNX?
Zogenix Inc. has had 6 recent analyst actions on file. The most recent action was from Northland Capital: Market Perform on 2022-02-28. Recent price targets range from $2300.00 to $4400.00.What companies are similar to ZGNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZGNX side-by-side with any of them on Quantisnow.How can I track ZGNX on Quantisnow?
Quantisnow aggregates Zogenix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZGNX to receive live email and push alerts on every new disclosure.